IGHE and asthma: Dupilumab significantly reduced severe asthma exacerbations and improved lung function in the seropositive ABPA group on the drug compared to the placebo, and also to a greater degree than in the large sample of non-ABPA asthmatics in the trial (Figure 4), while also significantly reducing total and Aspergillus-specific IgE levels, FENO and CCL17/TARC levels [82].